ორშაბათი, აპრილი 13, 2026
- Advertisement -
Google search engine
Global Ingredient Risk Index Omega / EFAs

Omega-3 Fatty Acids

Also known as: N-3 fatty acids, EPA, DHA, ALA

LOW RISK 2.0/10 How?

This ingredient is classified as unclassified risk (GIRI score: 2.0/10).

02

Safety Profile

Information not yet available for this ingredient profile.

═══════════════════════════════════════════════════════════════════════ -->
03

Interactions

Information not yet available for this ingredient profile.

═══════════════════════════════════════════════════════════════════════ -->
04

Evidence and Scientific Findings

Overview

Ingredient Overview

Omega-3 fatty acids from fish or plant sources are broadly recognised as beneficial for cardiovascular health. They are safe at dietary amounts. High supplemental doses (>3 g/day) can impair platelet function. Interaction with blood thinners such as warfarin and aspirin is possible. Choose high-quality, oxidation-tested products.

Classification

Biological and Chemical Classification

Information not yet available for this ingredient profile.

Mechanism

Mechanism of Action

Information not yet available for this ingredient profile.

Clinical Evidence

Clinical Evidence of Effectiveness

Information not yet available for this ingredient profile.

Pharmacokinetics

Pharmacokinetics

Information not yet available for this ingredient profile.

Dosage

Recommended Dosage

Information not yet available for this ingredient profile.

═══════════════════════════════════════════════════════════════════════ -->
05

SETI — Scientific Evidence Transparency Index

SETI Score 50/100
Risk Level High risk
Scientific Confidence Low
Evidence Strength Limited
Key Benefit Omega / EFAs
Evidence Reviewed 10 PubMed studies
Scientific Confidence Low
Based on study quality, consistency, and recency

Executive Summary — Ingredient Assessment

SETI Score 50/100
Risk Level High risk
Evidence Strength Limited
Main Benefit Omega / EFAs
Ingredient Omega-3 Fatty Acids
Scientific Evidence Overview
  • 10 studies reviewed
  • 0 high-quality studies (meta-analysis or RCT)
  • Main clinical benefit observed: Omega / EFAs
  • Evidence consistency: High consistency across studies (100%)
Safety Signals
  • No significant safety signals identified in the reviewed literature.
Evidence Strength Limited
Final Scientific Assessment

The available scientific evidence for Omega-3 Fatty Acids indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.

Ingredient Omega-3 Fatty Acids
Evidence reviewed 10 peer-reviewed studies (last 10 years)
50 /100

Total SETI Score

High risk
Evidence quality 10/40
Evidence consistency 20/20
Safety signals 0/20
Study recency 10/10
Evidence transparency 10/10

Evidence Summary

  • 10 studies reviewed
  • 0 high-quality studies (meta-analysis or systematic review)
  • 0 studies identified benefits or no safety concern (GREEN)
  • 10 studies reported limited or advisory safety evidence (YELLOW)

Evidence Policy

Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.

Last updated: 26 მარ 2026, 13:59

Evidence Distribution

10 Other / unclassified
  1. Observational / other LOW evidence YELLOW
    Effect of omega-3 supplementation on metabolic and inflammatory markers in adults with HIV infection: a systematic review and meta-analysis. ↗
    PMID 41883419 ↗
    Journal Front Nutr
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41883419/
    Bai J et al.. Effect of omega-3 supplementation on metabolic and inflammatory markers in adults with HIV infection: a systematic review and meta-analysis.. Front Nutr. 2026. PMID:41883419.
  2. Observational / other LOW evidence YELLOW
    Glycerophospholipids in dairy cow health and longevity: a review. ↗
    PMID 41883310 ↗
    Journal J Dairy Res
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41883310/
    Sheedy DB et al.. Glycerophospholipids in dairy cow health and longevity: a review.. J Dairy Res. 2026. PMID:41883310.
  3. Observational / other LOW evidence YELLOW
    Fish oil-derived eicosapentaenoic and docosahexaenoic acids enhances synthesis of pro-resolving oxylipins and improves growth performance and insulin sensitivity in feedlot cattle. ↗
    PMID 41883159 ↗
    Journal J Anim Sci
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41883159/
    Pittaluga AM et al.. Fish oil-derived eicosapentaenoic and docosahexaenoic acids enhances synthesis of pro-resolving oxylipins and improves growth performance and insulin sensitivity in feedlot cattle.. J Anim Sci. 2026. PMID:41883159.
  4. Observational / other LOW evidence YELLOW
    Nutritional pathways from treatment to management of sarcopenia in patients with gastric cancer: a narrative review. ↗
    PMID 41881664 ↗
    Journal Korean J Fam Med
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41881664/
    Swati et al.. Nutritional pathways from treatment to management of sarcopenia in patients with gastric cancer: a narrative review.. Korean J Fam Med. 2026. PMID:41881664.
  5. Observational / other LOW evidence YELLOW
    Metabolomic biomarkers enhance 10-year mortality risk calibration and clinical utility in older heart failure patients: A UK Biobank study. ↗
    PMID 41881269 ↗
    Journal Exp Gerontol
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41881269/
    Zeng X et al.. Metabolomic biomarkers enhance 10-year mortality risk calibration and clinical utility in older heart failure patients: A UK Biobank study.. Exp Gerontol. 2026. PMID:41881269.
  6. Observational / other LOW evidence YELLOW
    The Impact of Omega-3 Fatty Acids on Triglyceride Levels in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-Analysis of Randomized Controlled… ↗
    PMID 41878258 ↗
    Journal Diabetes Metab Syndr Obes
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41878258/
    Li L et al.. The Impact of Omega-3 Fatty Acids on Triglyceride Levels in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-Analysis of Randomized Controlled Trials with Subgroup Analysis by Diabetes Status.. Diabetes Metab Syndr Obes. 2026. PMID:41878258.
  7. Observational / other LOW evidence YELLOW
    Immunoregulatory role of resolvins in periodontal disease and treatment: a systematic review. ↗
    PMID 41877137 ↗
    Journal BMC Oral Health
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41877137/
    Abullais SS et al.. Immunoregulatory role of resolvins in periodontal disease and treatment: a systematic review.. BMC Oral Health. 2026. PMID:41877137.
  8. Observational / other LOW evidence YELLOW
    Nutraceuticals and the Microbiota-Gut-Brain Axis: A Pathway for Preventing Cognitive Decline. ↗
    PMID 41875216 ↗
    Journal Nutr Rev
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41875216/
    Castillo-Moral u00c1 et al.. Nutraceuticals and the Microbiota-Gut-Brain Axis: A Pathway for Preventing Cognitive Decline.. Nutr Rev. 2026. PMID:41875216.
  9. Observational / other LOW evidence YELLOW
    Upcycling walnut (Juglans regia L.) by-products: characterisation of nutritionally relevant bioactive compounds. ↗
    PMID 41873665 ↗
    Journal Food Funct
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41873665/
    Campins-Machado FM et al.. Upcycling walnut (Juglans regia L.) by-products: characterisation of nutritionally relevant bioactive compounds.. Food Funct. 2026. PMID:41873665.
  10. Observational / other LOW evidence YELLOW
    Robustness of highly purified eicosapentaenoic acid trials and their cardiovascular outcomes. ↗
    PMID 41870913 ↗
    Journal J Cardiovasc Med (Hagerstown)
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41870913/
    Zuin M et al.. Robustness of highly purified eicosapentaenoic acid trials and their cardiovascular outcomes.. J Cardiovasc Med (Hagerstown). 2026. PMID:41870913.
═══════════════════════════════════════════════════════════════════════ -->
06

Score Transparency

Q × L × D × S × 10 = 2.0 / 10

The GIRI Score is the product of four independently computed evidence components, each normalised to 0–1, then scaled to 0–10. Every component is derived exclusively from peer-reviewed references and regulatory data — no editorial judgement is applied.

Q
Evidence Quantity 0 / 10
0%

0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.

Method: Q = number of approved references ÷ 10 (capped at 1.0)

L
Evidence Quality 5 / 10
50%

Limited — mostly case reports or animal studies

Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.

D
Evidence Direction 5 / 10
Benefit
Risk
50%

Mixed or neutral — roughly equal benefit and risk signals

Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.

S
Safety Signals 5 / 10
50%

One or more monitoring-level safety signals active

Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.

0Q × 5L × 5D × 5S = 2.0 / 10

Final GIRI Score for Omega-3 Fatty Acids. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

Full methodology & data sources

The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.

  • References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
  • Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
  • Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
  • Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
07

Risk Level Classification

LOW RISK 2.0/10

Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.

LOW
0–3.0
MODERATE
3.0–5.5
HIGH
5.5–7.5
CRITICAL
7.5–10
2.0

The score pin shows exactly where this ingredient falls on the fixed risk scale.

What drove the Low classification for Omega-3 Fatty Acids

GIRI Score 2.0 / 10

A score of 2.0 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

Evidence Quantity (Q) 0 / 10 refs

0 approved references.

Evidence Quality (L) 50%

Limited — mostly case reports or animal studies (Level 4–5).

Evidence Direction (D) 50% toward risk

Neutral or mixed — benefit and risk signals roughly balanced.

Safety Signals (S) 0 active signals

No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.

Regulatory Status No restrictions found

No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).

How are the Low / Moderate / High / Critical thresholds defined?

The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:

LevelScoreMeaning
LOW0.0 – 2.9Sparse or predominantly beneficial evidence. No active safety alerts.
MODERATE3.0 – 5.4Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups.
HIGH5.5 – 7.4Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended.
CRITICAL7.5 – 10Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision.

Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.

← Back to Ingredient Database

ბოლო სიახლეები

პოპულარული ამბები

კატეგორიები

ჩვენ შესახებ

info@accreditation.ge
ჩვენს შესახებ / რეკლამა / კონტაქტი

გამოგვყევი სოციალურ ქსელებში

© SheniEkimi.ge